Combinations of PARP inhibitors with drugs that inhibit HR may sensitise EOC with a primary or secondary HR proficiency to PARP inhibitors and potentially expand their use beyond HR-deficient ovarian cancers. Here, PARP1 is linked to ovarian carcinoma.